CardioDynamics Announces Multi-Unit BioZ Shipment to SmithKline Beecham, United Kingdom for Drug Research and Development; Company also Announces BioZ.sim Market Release.

SAN DIEGO--(BW HealthWire)--Nov. 18, 1999--

CardioDynamics International Corp. (Nasdaq:CDIC), manufacturer of BioZ(R) noninvasive digital cardiac output monitoring systems, announced a multi-unit BioZ shipment to SmithKline Beecham, United Kingdom, a $12 billion world-leading healthcare company.

SmithKline Beecham selected the BioZ.com to aid in its ongoing drug research and development and has purchased 21 BioZ systems to date to aid in its drug discovery programs.

Jeffrey A. Price, technical coordinator of Clinical Pharmacology-Europe, SmithKline Beecham Pharmaceuticals, stated, "The BioZ.com is a necessary tool for our company to assess and document the lack of adverse cardiovascular effects resulting from our newly developed non-cardiovascular drugs. We selected the BioZ.com because of its ability to noninvasively monitor patient hemodynamic status and were impressed with its compact design, dependability, and ease-of-use. The BioZ.com is proving to be an effective and valuable component of our ongoing drug research and development."

Michael K. Perry, chief executive officer of CardioDynamics, stated, "One of the major benefits of the BioZ's proprietary Thoracic Electrical Bioimpedance (TEB) technology is its usefulness in a vast range of applications. The company is encouraged by increasing sales to the pharmaceutical sector, and has initiated a strategic marketing effort to further penetrate this opportunity and to explore additional clinical applications for our technology. We have also seen an increasing trend toward multiple system orders and view this important sale as continued validation of our technology's superiority to other available medical technologies."

The company also announced the global market release of the BioZ.sim. The BioZ.sim is a simulation and calibration tool that was specifically designed to allow end-users and hospital biomedical engineering departments to test and verify the functionality of their BioZ systems. The BioZ.sim will extend the clinical utility of the BioZ product line for the company's over 300 customers, which analysts project will increase to over 1,000 in the next year.

SmithKline Beecham (NYSE:SBH) -- one of the world's leading healthcare companies, discovers, develops, manufactures, and markets pharmaceuticals, vaccines, over-the-counter medicines, and health-related consumer products, and provides healthcare services including clinical laboratory testing, disease management, and pharmaceutical benefit management. For company information, please visit SmithKline Beecham on the World Wide Net at www.sb.com.

CardioDynamics, with headquarters in San Diego, is committed to fundamentally changing the way hemodynamic monitoring is performed in healthcare. The company's primary products, the BioZ(R) System, BioZ(TM) Portable, and BioZ.com(TM), utilize its Thoracic Electrical Bioimpedance (TEB) technology to noninvasively obtain data on a wide range of hemodynamic parameters. There are over 400 BioZ(R) systems now in use in physician offices and major medical centers including the Mayo Clinic (Rochester), UCSF Stanford Health Care (Palo Alto), Yale New Haven Hospital (New Haven), and Baylor College of Medicine (Houston). The worldwide market potential for BioZ products is estimated to be $4 billion, together with an additional $800 million in recurring annual revenue for disposables. For additional information, please refer to the company's Web site at www.cardiodynamics.com.

Forward-Looking (Safe Harbor) Statement:

Note: Except for the historical and factual information contained herein, this press release contains forward-looking statements, the accuracy of which are necessarily subject to uncertainties and risks, which include sole dependence on the BioZ product line, competition from Baxter Healthcare Corp. (manufacturer of the Swan-Ganz(TM) device), further capital requirements, and various uncertainties characteristic of companies just emerging from the development stage; as well as other risks detailed in the company's filings with the SEC, including its 1998 Form 10-KSB. The company does not undertake to update the disclosures contained in this press release.